Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH.
Desmedt, Christine PhD *; Sperinde, Jeff PhD +; Piette, Fanny PhD ++; Huang, Weidong MD, PhD +; Jin, Xueguang PhD +; Tan, Yuping PhD +; Durbecq, Virginie MD, PhD *; Larsimont, Denis MD, PhD *; Giuliani, Rosa MD, PhD *; Chappey, Colombe PhD +; Buyse, Marc PhD ++; Winslow, John PhD +; Piccart, Martine MD, PhD *; Sotiriou, Christos MD, PhD *; Petropoulos, Christos PhD +; Bates, Michael MD +
Diagnostic Molecular Pathology.
18(1):22-29, March 2009.
(Format: HTML, PDF)
The selection of patients with HER2-positive breast cancer for treatment with trastuzumab is based on the measurement of HER2 protein expression by immunohistochemistry, or the presence of HER2 gene amplification by fluorescence in situ hybridization (FISH). By using multivariate analyses, we investigate the relationship between quantitative measurements of HER2 expression or HER2:HER2 dimers and objective response (Response Evaluation Criteria in Solid Tumors), time to progression, and breast cancer survival after trastuzumab treatment in a cohort of patients with metastatic breast cancer who were primarily selected for treatment by FISH. The VeraTag assay, a proximity-based assay designed to quantitate protein expression and dimerization in formalin-fixed, paraffin-embedded tissue specimens, was used to measure HER2 protein expression and HER2:HER2 dimer levels. In a Cox proportional hazards analysis, higher HER2 expression or HER2:HER2 dimer levels were both correlated with longer survival (P=0.0058 and P=0.016, respectively) after treatment with trastuzumab in a population of patients that were either FISH-positive (90%) or immunohistochemistry 3 (10%). Patients with higher levels of HER2 expression or HER2:HER2 dimers seemed to derive little benefit from the addition of concomitant chemotherapy to trastuzumab, whereas those with lower levels benefited significantly [interaction test P=0.43 (HER2 expression), P=0.27 (HER2:HER2 dimers)]. These data suggest that more quantitative or functional measurements of HER2 status may facilitate the development of more personalized treatment strategies for patients with metastatic breast cancer.
(C) 2009 Lippincott Williams & Wilkins, Inc.